Last Price
22.94
Today's Change
-1.035 (4.31%)
Day's Change
22.36 - 24.08
Trading Volume
325,587
Market Cap
1 Billion
Shares Outstanding
57 Million
Avg Volume
754,232
Avg Price (50 Days)
20.20
Avg Price (200 Days)
13.47
PE Ratio
-7.33
EPS
-3.13
Earnings Announcement
08-Aug-2024
Previous Close
23.98
Open
23.82
Day's Range
22.36 - 24.08
Year Range
7.64 - 30.189
Trading Volume
325,701
1 Day Change
-4.32%
5 Day Change
-14.35%
1 Month Change
46.52%
3 Month Change
34.42%
6 Month Change
165.26%
Ytd Change
116.67%
1 Year Change
151.04%
3 Year Change
-15.61%
5 Year Change
-23.29%
10 Year Change
-23.29%
Max Change
-23.29%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.